Fidasimtamab, also known as DLTV – 1504, represents an innovative strategy in the battle against multiple myeloma. It is a dual-specific agent designed to simultaneously engage CD3-positive T cells and https://fidasimtamabbulk214892.blognody.com/52712780/fidasimtamab-a-promising-option-in-advanced-myeloma-treatment